Endologix Inc develops, manufactures, markets and sells medical devices for the treatment of aortic disorders. Its products are intended for the treatment of abdominal aortic aneurysms.
Endologix Adds Jane E. Kiernan to its Board of Directors
Mar 17, 2020 @ 22:30
Endologix, Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Jane E. Kiernan to its board of directors, effective March 12, 2020. Ms. Kiernan has also been appointed to...
Endologix Receives FDA Approval for Alto Abdominal Stent Graft System
Mar 16, 2020 @ 13:00
Endologix® Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that it has received approval from the United States Food and Drug Administration (FDA) for the Alto™ Abdominal Stent Graft System...
Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 06, 2020 @ 13:00
Endologix, Inc. (Nasdaq: ELGX) (the "Company"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of an inducement equity award to a newly hired employee (the "Awardee"). The award was approved by the Company’s Compensation Committee...
Endologix, Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, announced today that it has entered into an exchange agreement with three holders of the Company’s 3.25% Senior Convertible Notes due 2020 (the "...
Endologix (ELGX) delivered earnings and revenue surprises of 40.00% and -0.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?...
Endologix Reports Fourth Quarter and Fiscal Year 2019 Financial Results
Feb 19, 2020 @ 21:01
Endologix, Inc. (the "Company") (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the fourth quarter and fiscal year ended December 31, 2019....
Endologix, Inc. to Present at the SVB Leerink Global Healthcare Conference
Feb 18, 2020 @ 13:00
Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that Vaseem Mahboob, Chief Financial Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference at 3:00 p.m. ET on Wednesday, February 26, 2020 in New York, NY...